Agios Pharmaceuticals Inc

NASDAQ:AGIOUnited States

Today

Show headlines and story abstract

• Agios Says of Trial of Blood Disorder Drug Mitapivat Met Primary Endpoint; Shares Rise, from 7 hours ago by MT Newswires

  7 hours ago by MT Newswires
  Companies Mentioned: AGIO
  10:28 AM EDT, 06/03/2024 (MT Newswires) -- Agios Pharmaceuticals (AGIO) said Monday a phase 3 trial of mitapivat in adults with transfusion-dependent thalassemia achieved its primary endpoint of transfusion reduction response. The study also achieve...

• DJ Agios Pharmaceuticals Shares Rise 16% After Positive Trial Data for Mitapivat, from 7 hours ago by Dow Jones

  7 hours ago by Dow Jones
  Companies Mentioned: AGIO
  
  By Chris Wack
  
  Agios Pharmaceuticals shares were up 16% to $42 after the company said its global Phase 3 study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved its primary endpoint of transfusion reduction response.
  

• Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia, from 11 hours ago by Dow Jones

  11 hours ago by Dow Jones
  Companies Mentioned: AGIO
  
  This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding: the potential benefits of mitapivat; Agios' plans for the future clinical development of mitapivat in alpha-and-beta thalassemia; Agios' plans for future regulatory submissions; and Agios' strategic plans and prospects. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborators is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. Moreover, there can be no guarantee that any medicines ultimately commercialized by Agios will receive commercial acceptance. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to establish and maintain key collaborations; uncertainty regarding any milestone or royalty payments related to the sale of Agios' oncology business or its in-licensing of TMPRSS6 siRNA, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios' cash and cash equivalents; competitive factors; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.